Humira and the Reality of Pharmaceutical Advertising

This chapter critically examines the marketing of Humira and its implications for patients with Crohn's disease, highlighting the stark contrast between promotional cheerfulness and serious health risks. The discussion also includes a look at Abilify's role as an antidepressant, questioning the safety of its prescriptions for vulnerable patients.